These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34312963)

  • 21. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
    Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
    Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nusinersen for the treatment of spinal muscular atrophy.
    Chiriboga CA
    Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety analysis of laboratory parameters in paediatric patients with spinal muscular atrophy treated with nusinersen.
    Zhu X; Li H; Hu C; Wu M; Zhou S; Wang Y; Li W
    BMC Pediatr; 2024 Jul; 24(1):474. PubMed ID: 39054521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy.
    Errico F; Marino C; Grimaldi M; Nuzzo T; Bassareo V; Valsecchi V; Panicucci C; Di Schiavi E; Mazza T; Bruno C; D'Amico A; Carta M; D'Ursi AM; Bertini E; Pellizzoni L; Usiello A
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
    Roos A; Schmitt LI; Hansmann C; Hezel S; Salmanian S; Hentschel A; Meyer N; Marina AD; Kölbel H; Kleinschnitz C; Schara-Schmidt U; Leo M; Hagenacker T
    Acta Neuropathol; 2024 Mar; 147(1):53. PubMed ID: 38470509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland.
    Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M
    Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
    Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
    J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Children and young adults with spinal muscular atrophy treated with nusinersen.
    Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
    Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.
    Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R
    Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
    Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
    Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy.
    Kobayashi Y; Ishikawa N; Tateishi Y; Izumo H; Eto S; Eguchi Y; Okada S
    Brain Dev; 2023 Jan; 45(1):2-7. PubMed ID: 36210235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples.
    Welby E; Rehborg RJ; Harmelink M; Ebert AD
    Hum Mol Genet; 2022 Jun; 31(11):1830-1843. PubMed ID: 34919695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
    Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
    Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients?
    Introna A; Milella G; D'Errico E; Fraddosio A; Scaglione G; Ucci M; Ruggieri M; Simone IL
    Muscle Nerve; 2021 Jun; 63(6):905-909. PubMed ID: 33660868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofilament as a potential biomarker for spinal muscular atrophy.
    Darras BT; Crawford TO; Finkel RS; Mercuri E; De Vivo DC; Oskoui M; Tizzano EF; Ryan MM; Muntoni F; Zhao G; Staropoli J; McCampbell A; Petrillo M; Stebbins C; Fradette S; Farwell W; Sumner CJ
    Ann Clin Transl Neurol; 2019 May; 6(5):932-944. PubMed ID: 31139691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.